A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response
- Cite this article as:
- Pearlstein, T., Spurell, E., Hohlstein, L. et al. Arch Womens Ment Health (2003) 6: 147. doi:10.1007/s00737-003-0172-8
- 116 Downloads
Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.